EU Clinical Trial Regulation (EU CTR): Complete Guide for Sponsors

On 31 January 2022, the EU Clinical Trial Regulation — Regulation (EU) No 536/2014, known as the EU CTR — became fully applicable across all EU member states. After nearly a decade of preparation and a delayed rollout, it replaced the Clinical Trials Directive 2001/20/EC and fundamentally changed how clinical trials are authorised, conducted, and reported in the EU.

For sponsors running or planning clinical trials in Europe, the EU CTR is not a minor administrative update. It changes the authorisation process, the reporting obligations, the transparency requirements, and the regulatory relationship between sponsors and member states. Understanding it is essential before you submit your first trial application.

What Is the EU CTR and Why Did It Replace the 2001 Directive?

The EU CTR (Regulation (EU) No 536/2014) was adopted in 2014 to address the fundamental failures of the Clinical Trials Directive 2001/20/EC. The 2001 Directive was implemented differently across member states, creating a fragmented regulatory landscape where sponsors running multi-country trials had to navigate up to 27 separate national processes, timelines, and documentation requirements.

The result was predictable: clinical trial activity in the EU declined significantly between 2007 and 2017, with many sponsors choosing the USA or Asia for early-phase trials due to lower regulatory complexity.

The EU CTR introduced a single portal — the Clinical Trials Information System (CTIS) — and a harmonised authorisation procedure that allows sponsors to submit one application covering all participating EU member states simultaneously. The regulation also introduced mandatory transparency requirements, with trial data published on the CTIS portal.

What Is CTIS and How Does It Work?

CTIS (Clinical Trials Information System) is the EU-wide portal through which all clinical trial applications under the EU CTR must be submitted. It is managed by the European Medicines Agency (EMA) and accessible at clinicaltrialsregister.eu.

Under the EU CTR, the authorisation process works as follows:

1. Sponsor selects a Reporting Member State (RMS): The sponsor designates one EU member state as the RMS. The RMS leads the scientific assessment of the trial application.

2. Single application submission: The sponsor submits one application through CTIS covering all participating member states (Concerned Member States, or CMS).

3. Part I assessment (scientific/ethical): The RMS leads the assessment of Part I of the application — the scientific and clinical aspects of the trial protocol, investigational medicinal product (IMP) information, and GCP compliance. All CMS can comment, but the RMS decision on Part I is binding.

4. Part II assessment (national aspects): Each CMS independently assesses Part II — national-specific aspects including ethics committee opinion, informed consent procedures, and national legal requirements. Each CMS makes its own Part II decision.

5. Timelines: The total authorisation timeline is a maximum of 30 days for Part I assessment (extendable to 45 days for complex trials) and 30 days for Part II. This is significantly faster than the fragmented timelines under the 2001 Directive, where multi-country authorisation routinely took 6 to 12 months.

6. Authorisation: The trial is authorised in each member state where both Part I and Part II are approved.

Key Changes from the 2001 Directive

Aspect	Directive 2001/20/EC	Regulation (EU) No 536/2014 (EU CTR)
Application process	Separate national applications per country	Single CTIS application covering all member states
Assessment	Each country independently	RMS leads Part I; CMS assess Part II
Timeline	Variable (often 6-12 months for multi-country)	Maximum 30-45 days Part I + 30 days Part II
Transparency	Limited — EudraCT database, partial public access	Full public disclosure on CTIS within defined timelines
Transition	N/A	Trials authorised under 2001 Directive must transition to EU CTR by 31 January 2025
Scope	Clinical trials of medicinal products	All interventional clinical trials of medicinal products

The transition deadline is critical: any trial that was authorised under the 2001 Directive and was still ongoing after 31 January 2023 had to be transitioned to the EU CTR by 31 January 2025. Sponsors who missed this deadline faced significant regulatory complications.

What Does the EU CTR Require from Sponsors?

Before the Trial

Sponsors must submit a complete clinical trial application through CTIS. The application includes:

• Protocol: Full clinical trial protocol, including objectives, design, methodology, statistical considerations, and stopping rules
• Investigator’s Brochure (IB): Current version of the IB for the investigational medicinal product
• IMP dossier: Quality, non-clinical, and clinical data for the IMP, formatted according to the Common Technical Document (CTD) structure
• GMP compliance documentation: Evidence that the IMP is manufactured in accordance with EU GMP (EudraLex Volume 4)
• Informed consent forms: Templates for all participating countries, translated as required
• Ethics committee opinion: Required for Part II in each member state

During the Trial

Sponsors must report through CTIS:

• Substantial modifications: Any changes to the protocol, IMP, or other aspects of the trial that may affect subject safety or scientific validity require prior authorisation
• Serious Adverse Events (SAEs): Unexpected serious adverse reactions (SUSARs) must be reported to EMA and all affected member states within 7 days (fatal/life-threatening) or 15 days (other)
• Annual Safety Reports: Development Safety Update Reports (DSURs) must be submitted annually

After the Trial

• End of trial notification: Within 15 days of trial completion in each member state
• Clinical Study Report (CSR): Must be submitted within 12 months of trial completion (or 30 months for paediatric trials)
• Lay summary: A plain-language summary of results must be submitted within 12 months of trial completion and will be published on CTIS

The transparency requirements are a significant change from previous practice. Under the EU CTR, clinical trial results — including negative results — are published on CTIS. Sponsors cannot suppress unfavourable data.

What Is a Reporting Member State and How Do You Choose One?

The Reporting Member State (RMS) plays a central role in the EU CTR authorisation process. The RMS leads the Part I scientific assessment and its conclusions are binding on all Concerned Member States for Part I aspects.

Sponsors choose their RMS strategically. Factors to consider:

• Regulatory experience: Member states with strong regulatory agencies (Germany, France, Netherlands, Sweden) tend to have experienced assessors and predictable timelines
• Language: Sponsors may prefer an RMS where they have existing relationships or language capabilities
• Therapeutic area expertise: Some member states have particular expertise in specific therapeutic areas
• Principal investigator location: If your lead investigator is in France, ANSM as RMS may be the practical choice

France (ANSM) and Germany (BfArM/PEI) are the most commonly chosen RMS for complex trials. For smaller sponsors or early-phase trials, smaller member states can sometimes offer faster assessment timelines.

Practical Implications for North American Sponsors

For US and Canadian sponsors running their first EU clinical trial, the EU CTR represents both an opportunity and a compliance challenge.

The opportunity: a single application covering all EU member states means you can access the EU’s 450 million patient population through one regulatory process. The EU CTR’s harmonised timelines are genuinely faster than the pre-2022 system for multi-country trials.

The compliance challenge: the EU CTR’s documentation requirements are extensive, the CTIS portal has a learning curve, and the transparency obligations are more demanding than FDA requirements. Sponsors accustomed to FDA IND processes will find the EU CTR’s Part I/Part II structure unfamiliar.

Key differences from FDA IND:

• There is no equivalent of the FDA’s 30-day IND review period — EU CTR timelines are longer but more predictable
• EU CTR requires ethics committee approval as part of the authorisation process (Part II), whereas FDA separates IND approval from IRB approval
• EU CTR mandatory result publication has no direct FDA equivalent (though FDA requires registration on ClinicalTrials.gov)

At Care Europe, we support North American sponsors preparing their first EU CTR submissions, including RMS selection strategy, CTIS registration, and Part I/Part II documentation preparation.

The French Regulatory Context: ANSM and the EU CTR

In France, ANSM (Agence nationale de sécurité du médicament et des produits de santé) is the competent authority for clinical trial authorisation. ANSM has been an active participant in the EU CTR implementation and has published detailed guidance on its national requirements for Part II applications.

French-specific Part II requirements include:

• Ethics committee opinion from a Comité de Protection des Personnes (CPP) — France has 39 CPPs, and the CPP is randomly assigned through a national system
• Compliance with French law on bioethics (Loi Jardé, codified in the French Public Health Code)
• French-language informed consent forms for trials conducted in France

For sponsors designating ANSM as RMS, the French regulatory team at Care Europe can support both the Part I application and the French-specific Part II requirements.

---

The EU CTR has simplified multi-country clinical trial authorisation in the EU, but it has not simplified the underlying science or documentation requirements. Sponsors who invest in understanding the CTIS workflow, the Part I/Part II structure, and the transparency obligations before their first submission will find the process manageable. Those who approach it as a form-filling exercise tend to receive substantial modification requests that delay their trials by months.

Contact Care Europe at [email protected] to discuss EU CTR strategy for your next clinical programme.